IRIS
BUTTITTA, Fiamma
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 5.618
AS - Asia 3.700
EU - Europa 3.634
SA - Sud America 469
Continente sconosciuto - Info sul continente non disponibili 251
AF - Africa 52
OC - Oceania 10
Totale 13.734
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.475
SG - Singapore 1.543
CN - Cina 1.029
UA - Ucraina 540
IT - Italia 530
IE - Irlanda 481
GB - Regno Unito 447
SE - Svezia 401
RU - Federazione Russa 381
BR - Brasile 378
TR - Turchia 324
VN - Vietnam 318
FR - Francia 304
DE - Germania 251
IN - India 163
FI - Finlandia 117
CA - Canada 73
HK - Hong Kong 62
BD - Bangladesh 41
MX - Messico 41
PL - Polonia 39
AR - Argentina 37
IQ - Iraq 32
JP - Giappone 28
KR - Corea 27
CZ - Repubblica Ceca 25
NL - Olanda 21
BE - Belgio 20
ES - Italia 20
ID - Indonesia 20
TW - Taiwan 19
PK - Pakistan 16
EC - Ecuador 14
ZA - Sudafrica 14
AT - Austria 13
SA - Arabia Saudita 13
IL - Israele 10
LT - Lituania 10
VE - Venezuela 10
CO - Colombia 9
MA - Marocco 9
PY - Paraguay 9
CL - Cile 8
IR - Iran 8
MY - Malesia 8
AU - Australia 7
EU - Europa 7
JM - Giamaica 7
AE - Emirati Arabi Uniti 6
CH - Svizzera 6
LB - Libano 6
BA - Bosnia-Erzegovina 5
ET - Etiopia 5
JO - Giordania 5
KE - Kenya 5
TT - Trinidad e Tobago 5
CR - Costa Rica 4
TN - Tunisia 4
AZ - Azerbaigian 3
DZ - Algeria 3
EE - Estonia 3
EG - Egitto 3
NI - Nicaragua 3
NO - Norvegia 3
NZ - Nuova Zelanda 3
PH - Filippine 3
SN - Senegal 3
UG - Uganda 3
DK - Danimarca 2
HN - Honduras 2
MK - Macedonia 2
NP - Nepal 2
RO - Romania 2
RS - Serbia 2
SV - El Salvador 2
TH - Thailandia 2
UY - Uruguay 2
UZ - Uzbekistan 2
AM - Armenia 1
AO - Angola 1
BG - Bulgaria 1
BH - Bahrain 1
BM - Bermuda 1
BN - Brunei Darussalam 1
BO - Bolivia 1
BS - Bahamas 1
BY - Bielorussia 1
GA - Gabon 1
GD - Grenada 1
GR - Grecia 1
GT - Guatemala 1
HU - Ungheria 1
KG - Kirghizistan 1
KZ - Kazakistan 1
LA - Repubblica Popolare Democratica del Laos 1
LI - Liechtenstein 1
LU - Lussemburgo 1
LV - Lettonia 1
MD - Moldavia 1
MM - Myanmar 1
Totale 13.482
Salva come PNG Salva come JPEG
Città #
Singapore 1.157
Chandler 654
San Jose 626
Jacksonville 612
Dublin 471
Ashburn 363
Beijing 270
Southend 264
Council Bluffs 232
Princeton 231
Dallas 200
Izmir 188
Nanjing 186
Los Angeles 149
Santa Clara 144
Cambridge 101
Dearborn 101
Ho Chi Minh City 95
New York 94
The Dalles 90
Wilmington 90
Tongling 82
Altamura 71
Boardman 70
Ann Arbor 67
Chieti 63
Munich 63
Hanoi 62
Nanchang 57
Hong Kong 54
Pescara 51
Buffalo 50
Shenyang 49
Moscow 38
São Paulo 36
Warsaw 32
Milan 31
Tianjin 29
Hangzhou 27
Rome 27
Hebei 26
Seoul 26
Woodbridge 26
Atlanta 25
Chennai 25
Orem 24
Redondo Beach 24
Denver 23
Kunming 23
Phoenix 23
Brooklyn 22
Stockholm 22
Grevenbroich 21
Montreal 21
Tokyo 21
Washington 21
Boston 20
Augusta 18
Chicago 18
Toronto 18
Houston 17
Mexico City 17
Brussels 16
London 16
Poplar 16
Baghdad 15
Da Nang 15
Jiaxing 15
Columbus 14
Helsinki 14
Jinan 14
Norwalk 14
San Mateo 14
Taichung 14
Biên Hòa 13
Brno 13
Ningbo 13
Belo Horizonte 12
Collecorvino 12
Rio de Janeiro 12
Frankfurt am Main 11
New Delhi 11
Orange 11
Turku 11
Changsha 10
Nuremberg 10
Haiphong 9
Hefei 9
Dong Ket 8
Johannesburg 8
Latina 8
Montesilvano 8
Mumbai 8
Ninh Bình 8
San Francisco 8
Vienna 8
Amsterdam 7
Auburn Hills 7
Guangzhou 7
Hyderabad 7
Totale 8.184
Salva come PNG Salva come JPEG
Nome #
Assessing EGFR mutations. 256
ALK protein analysis by IHC staining after recent regulatory changes: A comparison of two widely used approaches, revision of the literature, and a new testing algorithm 220
A unique microRNA signature associated with plaque instability in humans. 212
Assessment of EGFR mutations in circulating tumor cell preparations from NSCLC patients by next generation sequencing: Toward a real-time liquid biopsy for treatment 204
Validation of a new algorithm for a quick and easy RT-PCR-based ALK test in a large series of lung adenocarcinomas: Comparison with FISH, immunohistochemistry and next generation sequencing assays 187
ALK rearrangement testing by FISH analysis in non-small-cell lung cancer patients: Results of the first italian external quality assurance scheme 184
Effective assessment of egfr mutation status in bronchoalveolar lavage and pleural fluids by next-generation sequencing. 180
Multicenter Comparison of 22C3 PharmDx (Agilent) and SP263 (Ventana) Assays to Test PD-L1 Expression for NSCLC Patients to Be Treated with Immune Checkpoint Inhibitors 162
A unique microRNA signature associated with ischemic stroke in humans 159
Plasma exosome microRNA profiling unravels a new potential modulator of adiponectin pathway in diabetes: effect of glycemic control 159
EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment. 156
ROS1 Gene Fusion in Advanced Lung Cancer in Women: A Systematic Analysis, Review of the Literature, and Diagnostic Algorithm 154
Association between prostaglandin E receptor subtype EP4 overexpression and unstable phenotype in atherosclerotic plaques in human. 151
AKT1(E17K) in human solid tumours 150
Down regulation of high in normal-1 (HIN-1) is a frequent event in stage I non-small cell lung cancer and correlates with poor clinical outcome. 148
Mutational profile of GNAQQ209 in human tumors. 145
Different prognostic roles of mutations in the helical and kinase domains of the PIK3CA gene in breast carcinomas. 143
ABCA-1 expression is reduced in atherosclerotic plaques from hypertensive patients: a new potential link between hypertension and atherosclerosis 143
Extraordinary and prolonged erlotinib-induced clinical response in a patient with EGFR wild-type squamous lung cancer in third-line therapy: A case report 143
Mutational analysis of the HER2 gene in lung tumors from Caucasian patients: mutations are mainly present in adenocarcinomas with bronchioloalveolar features. 142
ATP-binding cassette transporter A1 (ABCA1) overexpression in hypercholesterolemic plaques: a potential molecular explanation 142
Why anti-PD1/PDL1 therapy is so effective? Another piece in the puzzle 142
Reduction of atherothrombotic burden before stent deployment in non-ST elevation acute coronary syndromes: Reduction of myocardial necrosis achieved with nose-dive manual thrombus aspiration (REMNANT) trial. A volumetric intravascular ultrasound study 142
POLE exonuclease domain mutations in endometrial carcinoma: a case report 141
Clinical features and outcome of patients with non-small-cell lung cancer harboring BRAF mutations. 141
Int6 expression can predict survival in early-stage non-small cell lung cancer patients. 141
Dramatic response to crizotinib in ROS1 fluorescent in situ hybridization- and immunohistochemistry-positive lung adenocarcinoma: a case series. 138
Alterations of P16 (MTS1) in node-positive non-small cell lung carcinomas. 136
Human telomerase reverse transcriptase mRNA expression assessed by real-time reverse transcription polymerase chain reaction predicts chemosensitivity in patients with ovarian carcinoma. 136
Overexpression of ABCA1 in human plaques exposed to hypercholesterolemia: the role of microRNA modulation 136
Optimizing Single Agent Panitumumab Therapy in Pre-Treated Advanced Colorectal Cancer 133
Complex Mutations & Subpopulations of Deletions at Exon 19 of EGFR in NSCLC Revealed by Next Generation Sequencing: Potential Clinical Implications. 132
Weekly alternate intensive regimen FIrB/FOx in metastatic colorectal cancer patients: An update from clinical practice 132
Identification of an aberrantly spliced form of HDMX in human tumors: a new mechanism for HDM2 stabilization. 131
Absence of somatic mutations in the coding region of the waf1/cip1 gene in human breast, lung and ovarian carcinomas - a polymorphism at codon-31. 130
Quantification of EGFR Mutations in Plasma of NSCLC Patients: An Early Predictor of Clinical Response to Tyrosine Kinase Inhibitor 130
Prediction of survival in stage I lung carcinoma patients by telomerase function evaluation 128
Survivin gene expression in early-stage non-small cell lung cancer. 127
PIK3CA mutation and histological type in breast carcinoma: high frequency of mutations in lobular carcinoma. 127
Increased MET gene copy number negatively affects survival of surgically resected non-small-cell lung cancer patients. 127
Early prediction of resistance to tyrosine kinase inhibitors by plasma monitoring of EGFR mutations in NSCLC: A new algorithm for patient selection and personalized treatment 127
Association between cigarette smoking and FHIT gene alterations in lung cancer. 126
Gene mutations in small-cell lung cancer (SCLC): Results of a panel of 6 genes in a cohort of Italian patients 126
An innovative diagnostic strategy for the detection of rare molecular targets to select cancer patients for tumor-agnostic treatments 123
Correspondence - In Reply - Limitations of Single-Strand Conformation Polymorphism Analysis As a High-Throughput Method for the Detection of EGFR Mutations in the Clinical Setting 122
Frequent mutations in the neurotrophic tyrosine receptor kinase gene family in large cell neuroendocrine carcinoma of the lung. 121
Survival prediction of stage I lung adenocarcinomas by expression of 10 genes. 121
Hypertension is a determinant of ABCA1 expression in atherosclerotic plaques from hypercholesterolemic patients 121
microRNAs Derived from Circulating Exosomes as Noninvasive Biomarkers for Screening and Diagnosing Lung Cancer. 121
mRNA markers of breast cancer nodal metastases: comparison between mammaglobin and carcinoembryonic antigen in 248 patients. 120
p53 alterations in non-small cell lung cancer correlate with metastatic involvement of hilar and mediastinal lymph nodes 120
IDH1 mutations at residue p.R132 (IDH1(R132)) occur frequently in high-grade gliomas but not in other solid tumors. 120
Recommendations for the implementation of BRCA testing in ovarian cancer patients and their relatives 120
EGFR molecular profiling in advanced NSCLC: a prospective phase II study in molecularly/clinically selected patients pretreated with chemotherapy. 119
Increased detection sensitivity for KRAS mutations enhances the prediction of anti-EGFR monoclonal antibody resistance in metastatic colorectal cancer. 119
Lung tumours from non-smoking subjects: A p53-related genetic instability in a subset of cases. 118
Prognostic value of p21(WAF1) and p53 expression in breast carcinoma: an immunohistochemical study in 261 patients with long-term follow-up 118
Adjuvant osimertinib treatment in patients with early stage NSCLC (IB-IIIA): pathological pathway adaptations 118
Telomerase activity as a prognostic indicator in Stage I Non- Small Cell Lung Cancer -Gruppo Italiano di Patologia Molecolare II Riunione Scientifica. Pisa 20-22 Giugno99 116
mdm2 gene alterations and mdm2 protein expression in breast carcinomas 116
Activating c-KIT mutations in a subset of thymic carcinoma and response to different c-KIT inhibitors. 115
The chromosomal location of the mouse mammary tumor gene Int6 and related pseudogenes in the mouse genome. 114
Early prediction of response to tyrosine kinase inhibitors by quantification of EGFR mutations in plasma of NSCLC patients 114
MDM4 (MDMX) localizes at the mitochondria and facilitates the p53-mediated intrinsic-apoptotic pathway. 113
Host genetic background effect on the frequency of mouse mammary tumor virus-induced rearrangements of the int-1 and int-2 loci in mouse mammary tumors. 111
Clinical implications of KRAS mutations in lung cancer patients treated with tyrosine kinase inhibitors: an important role for mutations in minor clones. 111
Hypertension modulates miR-145 expression in human atherosclerotic plaques 111
Enriched SSCP: a highly sensitive method for the detection of unknown mutations. Application to the molecular diagnosis of lung cancer in sputum samples. 110
The chromosome location of the human homolog of the mouse mammary tumor-associated gene INT6 and its status in human breast carcinomas. 109
The Integrated Oncology Program of the Italian Ministry of Health. Analytical and clinical validation of new biomarkers for early diagnosis: network, resources, methodology, quality control, and data analysis. 109
The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies 109
Int-6, a highly conserved, widely expressed gene, is mutated by mouse mammary tumor virus in mammary preneoplasia. 106
Nucleotide and deduced amino acid sequences of tumor gene INT6. 105
Assessment of the prognostic relevance of serum anti-p53 antibodies in epithelial ovarian cancer. 103
Genetic analysis of lung tumors of non-smoking subject: p53 gene mutations are constantly associated with loss of heterozygosity at the FHIT locus 102
Detection of gene mutations on cytological specimens: clinical implications 102
Clinical significance of cyclin D1 expression in patients with node-positive breast carcinoma treated with adjuvant therapy. 101
BRAF as a positive predictive biomarker: Focus on lung cancer and melanoma patients 101
Bronchioloalveolar carcinoma: K-ras mutations are constant events in the mucinous subtype 100
Prostatic cancer: molecular bases. 100
Telomerase Activity as a Prognostic Indicator in Stage I Non-Small Cell Lung Cancer 98
PI3KCA mutation status is of limited prognostic relevance in ER-positive breast cancer patients treated with hormone therapy 98
Real-world data on NGS diagnostics: A survey from the Italian Society of Pathology (SIAPeC) NGS Network 97
Identification of microRNAs 758 and 33b as potential modulators ofABCA1 expression in human atherosclerotic plaques 95
p53 mutations and histologic type of invasive breast carcinoma. A polymerase chain reaction-single-strand conformation polymorphism and immunohistochemical analysis. 94
p21 RNA and protein expression in non-small cell lung carcinomas: evidence of p53-independent expression and association with tumoral differentiation. 94
Predictive markers in lung cancer: A few hints for the practicing pathologist 94
Evaluation of FHIT gene alterations in ovarian cancer 92
BRCA gene amplification in primary peritoneal high-grade serous carcinoma patient with intrinsic resistance to platinum treatment: a case report 91
Serum anti-p53 antibodies in the follow-up of patients with advanced ovarian carcinoma. 91
p53 mutations and histological type of invasive breast carcinoma. 90
p21WAF1 immunohistochemical expression in breast carcinoma: correlations with clinicopathological data, oestrogen receptor status, MIB1 expression, p53 gene and protein alterations and relapse-free survival. 88
Stabilita’ del dna in campioni citologici conservati in fase liquida 88
Cyclin-D1-gene amplification and expression in breast carcinoma: relation with clinicopathologic characteristics and with retinoblastoma gene product, p53 and p21WAF1 immunohistochemical expression. 86
Consensus for EGFR mutation testing in non-small cell lung cancer: results from a European workshop. 85
Multiple regions of chromosome 6q affected by loss of heterozygosity in primary human breast carcinomas. 84
Expression of 90K (Mac-2 BP) correlates with distant metastasis and predicts survival in stage I non-small cell lung cancer patients 84
Reduced expression of INT-6/eIF3-p48 in human tumors. 84
Preoperative serum antibodies against the p53 protein in patients with ovarian and endometrial cancer. 82
Implementation of preventive and predictive BRCA testing in patients with breast, ovarian, pancreatic, and prostate cancer: a position paper of Italian Scientific Societies 81
Totale 12.444
Salva come PNG Salva come JPEG
Categoria #
all - tutte 55.722
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 55.722
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022578 0 0 8 131 31 23 13 38 50 33 84 167
2022/20231.709 144 216 70 212 193 345 96 105 233 12 46 37
2023/2024762 68 24 44 23 50 229 153 33 4 27 2 105
2024/20252.249 114 451 376 49 56 74 81 88 235 103 246 376
2025/20264.256 351 245 376 563 478 283 626 280 424 332 231 67
2026/2027351 74 211 66 0 0 0 0 0 0 0 0 0
Totale 13.734